Supernus director awarded RSUs and stock options

Supernus Pharmaceuticals director Charles W. Newhall III reported equity awards consisting of 2,989 restricted stock units and options for 4,977 shares, both granted on February 18, 2026.

Accepted by SEC EDGAR 02/20/2026 - 04:40 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Supernus Pharmaceuticals director Charles W. Newhall III reported equity awards consisting of 2,989 restricted stock units and options for 4,977 shares, both granted on February 18, 2026. Each restricted stock unit converts into one share, and both the RSUs and options vest on February 18, 2027.

Insider Trade Summary

Grant/Award: 7,966 shares

Grant/Award 2 txns

Insider NEWHALL CHARLES W III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	2,989	$0.00	$0.00
Grant/Award	Director Stock Option (Right to Buy)	4,977	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 2,989 contracts (Direct); Director Stock Option (Right to Buy) — 4,977 contracts (Direct)

Holdings Before and After: Restricted Stock Unit, 0 to 2,989 contracts (Direct); Director Stock Option (Right to Buy), 0 to 4,977 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
2. F2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
3. F3. Each option vests on February 18, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SUPN director Charles W. Newhall III report?

Charles W. Newhall III reported grants of equity awards, not open-market trades. He received 2,989 restricted stock units and options for 4,977 shares, all granted on February 18, 2026, with future vesting conditions attached to these awards.

How many restricted stock units were granted to the SUPN director?

The director received 2,989 restricted stock units. Each unit represents the right to receive one share of Supernus Pharmaceuticals common stock upon vesting, aligning director compensation with shareholder value over time through stock-based incentives rather than immediate cash payments.

What stock options were granted in this SUPN Form 4 filing?

The filing shows a grant of director stock options for 4,977 shares. These options are rights to buy Supernus common stock in the future, subject to vesting on February 18, 2027, which encourages longer-term board alignment with company performance.

When do the granted SUPN restricted stock units vest?

The restricted stock units vest on February 18, 2027. At that time, each unit will be settled in Supernus common stock, meaning the director becomes entitled to receive one common share for each vested unit, assuming continued satisfaction of vesting conditions.

When do the SUPN director stock options reported here vest?

The director stock options vest on February 18, 2027. Vesting means the options become exercisable on that date, allowing the director to purchase Supernus common shares under the option terms, which typically support long-term incentive compensation for board members.

Are the SUPN insider transactions purchases or grants?

These transactions are grants of awards, not market purchases or sales. The Form 4 uses code “A” for grant or award, reflecting equity compensation in the form of restricted stock units and director stock options, both recorded as acquisitions for reporting purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEWHALL CHARLES W III

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/18/2026		A		2,989		(2)	(2)	Common Stock	2,989	$0	2,989	D
Director Stock Option (Right to Buy)	$50.2	02/18/2026		A		4,977		(3)	02/18/2036	Common Stock	4,977	$0	4,977	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.

3. Each option vests on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.